|
Wow....
|
2
|
Resverlogix Corp.
|
Dec 23, 2020 02:16AM
|
|
Re: Shake it Up!
|
4
|
Resverlogix Corp.
|
Dec 22, 2020 08:02PM
|
|
Re: Shake it Up!
|
|
Resverlogix Corp.
|
Dec 22, 2020 07:33PM
|
|
Re: Shake it Up!
|
3
|
Resverlogix Corp.
|
Dec 22, 2020 07:15PM
|
|
Re: Shake it Up!
|
4
|
Resverlogix Corp.
|
Dec 22, 2020 06:38PM
|
|
Re: Shake it Up!
|
5
|
Resverlogix Corp.
|
Dec 22, 2020 06:04PM
|
|
Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial
|
|
Resverlogix Corp.
|
Dec 22, 2020 05:42PM
|
|
Is it safe to say....
|
1
|
Resverlogix Corp.
|
Dec 22, 2020 04:57PM
|
|
Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial
|
|
Resverlogix Corp.
|
Dec 22, 2020 04:45PM
|
|
Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial
|
|
Resverlogix Corp.
|
Dec 22, 2020 04:26PM
|
|
Re: Anyone.....
|
|
Resverlogix Corp.
|
Dec 22, 2020 03:53PM
|
|
Re: Anyone.....
|
|
Resverlogix Corp.
|
Dec 22, 2020 03:29PM
|
|
Re: Anyone.....
|
1
|
Resverlogix Corp.
|
Dec 22, 2020 03:12PM
|
|
Re: Anyone.....
|
1
|
Resverlogix Corp.
|
Dec 22, 2020 03:09PM
|
|
Re: Anyone.....
|
1
|
Resverlogix Corp.
|
Dec 22, 2020 02:59PM
|
|
Anyone.....
|
5
|
Resverlogix Corp.
|
Dec 22, 2020 02:46PM
|
|
Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial
|
1
|
Resverlogix Corp.
|
Dec 22, 2020 11:10AM
|
|
Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial
|
4
|
Resverlogix Corp.
|
Dec 22, 2020 08:59AM
|
|
Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial
|
5
|
Resverlogix Corp.
|
Dec 22, 2020 08:13AM
|
|
Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial
|
2
|
Resverlogix Corp.
|
Dec 22, 2020 08:02AM
|
